Cover Image

Update breast cancer 2021 part 4 - Prevention and early stages = Update Mammakarzinom 2021 Teil 4 - Prävention und frühe Krankheitsstadien

This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In t...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomssen, Christoph (Author) , Fehm, Tanja (Author) , Stickeler, Elmar (Author) , Fasching, Peter A. (Author) , Janni, Wolfgang (Author) , Kolberg-Liedtke, Cornelia (Author) , Kolberg, Hans-Christian (Author) , Lüftner, Diana (Author) , Müller, Volkmar (Author) , Schütz, Florian (Author) , Belleville, Erik (Author) , Bader, Simon (Author) , Untch, Michael (Author) , Welslau, Manfred (Author) , Thill, Marc (Author) , Hartkopf, Andreas D. (Author) , Tesch, Hans (Author) , Ditsch, Nina (Author) , Lux, Michael P. (Author) , Wöckel, Achim (Author) , Aktas, Bahriye (Author) , Schneeweiss, Andreas (Author) , Würstlein, Rachel (Author)
Format: Article (Journal)
Language:English
Published: [2022]
In: Geburtshilfe und Frauenheilkunde
Year: 2022, Volume: 82, Issue: 2, Pages: 206-214
ISSN:1438-8804
DOI:10.1055/a-1724-9639
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1724-9639
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1724-9639
Get full text
Author Notes:authors: Christoph Thomssen, Tanja N. Fehm, Elmar Stickeler, Peter A. Fasching, Wolfgang Janni, Cornelia Kolberg-Liedtke, Hans-Christian Kolberg, Diana Lüftner, Volkmar Müller, Florian Schütz, Erik Belleville, Simon Bader, Michael Untch, Manfred Welslau, Marc Thill, Andreas D. Hartkopf, Hans Tesch, Nina Ditsch, Michael P. Lux, Achim Wöckel, Bahriye Aktas, Andreas Schneeweiss, Rachel Würstlein
Description
Summary:This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In triple-negative disease, data were presented for two treatment regimens. Patients with advanced disease (stage 2 and 3) benefit from neoadjuvant treatment with the immune checkpoint inhibitor pembrolizumab in combination with standard chemotherapy, regardless of PD-L1 expression. When neoadjuvant therapy has failed to achieve the desired remission in BRCA1 and BRCA2 mutations, the administration of the PARP inhibitor olaparib has demonstrated an impressive response. Other data address translational issues in HER2-positive breast cancer and neoadjuvant therapy approaches with the oral SERD giredestrant and the PARP inhibitor talazoparib. This review presents and analyses the findings of this yearʼ s most important study outcomes.</p>
Item Description:Gesehen am 16.11.2022
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1724-9639

Similar Items